Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry
Published version of a preprint
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the detected PTMs were oxidation (M), deamidation (Q and N), dehydration, acetylation, cysteinylation, and others, consistent with known modifications of HLA-presented antigens, in source fragmentation of peptide ions or artefacts induced by sample processing (Supplementary Fig. S3A)35–38.”
From Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
UpSetR: an R package for the visualization of intersecting sets and their properties
Conway, J. R., Lex, A., & Gehlenborg, N. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx364 · Cited by 3,586
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Perineuronal nets stabilize the grid cell network
Christensen, A. C., Lensjø, K. K., Lepperød, M. E., Dragly, S.-A., Sutterud, H., Blackstad, J. S., Fyhn, M., & Hafting, T. (2021) · Nature Communications · doi:10.1038/s41467-020-20241-w · Cited by 1,865
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
The ins and outs of MHC class II-mediated antigen processing and presentation
Roche, P. A., & Furuta, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3818 · Cited by 1,207
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846
Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox
Oh, D. Y., & Fong, L. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.015 · Cited by 467 · cited 1×
“In addition, cytotoxic CD4+ T cells can secrete granzyme B and perforin to kill the tumor cells in an HLA-II-restricted manner (18).”
BackgroundO’Donnell, T. J., Rubinsteyn, A., & Laserson, U. (2020) · Cell Systems · doi:10.1016/j.cels.2020.06.010 · Cited by 440
Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002071 · Cited by 250
Identification of tumor antigens with immunopeptidomics
Chong, C., Coukos, G., & Bassani-Sternberg, M. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01038-8 · Cited by 232 · cited 1×
“Because of these expression patterns and the welldocumented cytotoxic activity of CD8+ T cells, HLA-I tumor immunopeptidomes are most frequently studied (1, 5, 8).”
Background
Research works printed but not linked: 42
- Guedan, 2019, Emerging cellular therapies for cancer, Annu. Rev. Immunol., 37, 145, 10.1146/annurev-immunol-042718-041407 · DOI · Paper page
- Ouspenskaia, 2022, Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer, Nat. Biotechnol., 40, 209, 10.1038/s41587-021-01021-3 · DOI · Paper page
- Smart, 2018, Intron retention is a source of neoepitopes in cancer, Nat. Biotechnol., 36, 1056, 10.1038/nbt.4239 · DOI · Paper page
- Dendrou, 2018, HLA variation and disease, Nat. Rev. Immunol., 18, 325, 10.1038/nri.2017.143 · DOI · Paper page
- Taylor, 2021, MS-based HLA-II Peptidomics combined with multiomics will aid the development of future immunotherapies, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100116 · DOI
- Cattaneo, 2023, Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens, Nat. Biotechnol., 10.1038/s41587-022-01547-0 · DOI
- Friedman, 2012, Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes, J. Immunother., 35, 400, 10.1097/CJI.0b013e31825898c5 · DOI
- Kitano, 2013, Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients, Cancer Immunol. Res., 1, 235, 10.1158/2326-6066.CIR-13-0068 · DOI · Paper page
- Tran, 2014, Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, Science, 344, 641, 10.1126/science.1251102 · DOI · Paper page
- Abelin, 2019, Defining HLA-II Ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction, Immunity, 51, 766, 10.1016/j.immuni.2019.08.012 · DOI · Paper page
- Hunt, 1992, Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry, Science, 255, 1261, 10.1126/science.1546328 · DOI · Paper page
- Stopfer, 2021, 1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs, Immunooncol. Technol., 11
- Becker, 2022, The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies, Front. Immunol., 13, 10.3389/fimmu.2022.883989 · DOI
- Shapiro, 2023, The impact of immunopeptidomics: from basic research to clinical implementation, Semin. Immunol., 66, 10.1016/j.smim.2023.101727 · DOI
- Chong, 2018, High-throughput and sensitive immunopeptidomics platform reveals profound interferonγ-mediated remodeling of the human leukocyte antigen (HLA) ligandome, Mol. Cell. Proteomics, 17, 533, 10.1074/mcp.TIR117.000383 · DOI · Paper page
- Klaeger, 2021, Optimized liquid and gas phase fractionation increases HLA-peptidome coverage for primary cell and tissue samples, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100133 · DOI
- Meier, 2021, Deep learning the collisional cross sections of the peptide universe from a million experimental values, Nat. Commun., 12, 1, 10.1038/s41467-021-21352-8 · DOI
- Casasola-LaMacchia, 2022, HLAII peptide presentation of infliximab increases when complexed with TNF, Front. Immunol., 13, 10.3389/fimmu.2022.932252 · DOI
- Nelde, 2022, Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity, iScience, 25, 10.1016/j.isci.2022.105643 · DOI
- Jaeger, 2022, Deciphering the immunopeptidome in vivo reveals new tumour antigens, Nature, 607, 149, 10.1038/s41586-022-04839-2 · DOI
- Abelin, 2023, Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues, Nat. Commun., 14, 1851, 10.1038/s41467-023-37547-0 · DOI
- Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI · Paper page
- Sarkizova, 2020, A large peptidome dataset improves HLA class I epitope prediction across most of the human population, Nat. Biotechnol., 38, 199, 10.1038/s41587-019-0322-9 · DOI · Paper page
- Kong, 2017, MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics, Nat. Methods, 14, 513, 10.1038/nmeth.4256 · DOI · Paper page
- Yu, 2020, Fast quantitative analysis of timsTOF PASEF data with MSFragger and IonQuant, Mol. Cell. Proteomics, 19, 1575, 10.1074/mcp.TIR120.002048 · DOI · Paper page
- Yu, 2021, IonQuant enables accurate and sensitive label-free quantification with FDR-controlled match-between-runs, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100077 · DOI · Paper page
- da Veiga Leprevost, 2020, Philosopher: a versatile toolkit for shotgun proteomics data analysis, Nat. Methods, 17, 869, 10.1038/s41592-020-0912-y · DOI · Paper page
- Kaczmarek, 2007, Analysis of expression of MHC class I molecules and TAP genes in malignant human cell lines, Folia Histochem. Cytobiol., 45, 205
- Mangalaparthi, 2021, Digging deeper into the immunopeptidome: characterization of post-translationally modified peptides presented by MHC I, J. Proteins Proteom., 12, 151, 10.1007/s42485-021-00066-x · DOI
- Ridgeway, 2018, Trapped ion mobility spectrometry: a short review, Int. J. Mass Spectrom., 425, 22, 10.1016/j.ijms.2018.01.006 · DOI · Paper page
- Fernandez-Lima, 2011, Gas-phase separation using a trapped ion mobility spectrometer, Int. J. Ion Mobil. Spectrom., 14, 10.1007/s12127-011-0067-8 · DOI · Paper page
- Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res., 37, D816, 10.1093/nar/gkn673 · DOI · Paper page
- Scanlan, 2002, Cancer/testis antigens: an expanding family of targets for cancer immunotherapy, Immunol. Rev., 188, 22, 10.1034/j.1600-065X.2002.18803.x · DOI · Paper page
- Erhard, 2020, Identification of the Cryptic HLA-I immunopeptidome, Cancer Immunol. Res., 8, 1018, 10.1158/2326-6066.CIR-19-0886 · DOI · Paper page
- Yewdell, 2022, MHC class I immunopeptidome: past, present, and future, Mol. Cell. Proteomics, 21, 10.1016/j.mcpro.2022.100230 · DOI
- Chong, 2020, Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes, Nat. Commun., 11, 1293, 10.1038/s41467-020-14968-9 · DOI · Paper page
- Ruiz Cuevas, 2021, Most non-canonical proteins uniquely populate the proteome or immunopeptidome, Cell Rep., 34, 10.1016/j.celrep.2021.108815 · DOI · Paper page
- Chen, 2022, PredMHC: an effective predictor of major histocompatibility complex using mixed features, Front. Genet., 13
- Jurtz, 2017, NetMHCpan-4.0: improved peptide-MHC class I interaction predictions Integrating eluted Ligand and peptide binding Affinity data, J. Immunol., 199, 3360, 10.4049/jimmunol.1700893 · DOI · Paper page
- Pak, 2021, Sensitive immunopeptidomics by leveraging available large-scale multi-HLA spectral Libraries, data-independent acquisition, and MS/MS prediction, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100080 · DOI
- Shahbazy, 2023, Benchmarking bioinformatics pipelines in data-independent acquisition mass spectrometry for immunopeptidomics, Mol. Cell. Proteomics, 22, 10.1016/j.mcpro.2023.100515 · DOI
- Xin, 2022, A streamlined platform for analyzing tera-scale DDA and DIA mass spectrometry data enables highly sensitive immunopeptidomics, Nat. Commun., 13, 3108, 10.1038/s41467-022-30867-7 · DOI
Cited by
Skowronek, P., Wallmann, G., Wahle, M., Willems, S., & Mann, M. (2025) · Nature Protocols · doi:10.1038/s41596-024-01104-w · Cited by 43
Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes
Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51959-6 · Cited by 12
Metadata
- Authors
- Phulphagar, K. M., Ctortecka, C., Jacome, A. S. V., Klaeger, S., Verzani, E. K., Hernandez, G. M., Udeshi, N. D., Clauser, K. R., Abelin, J. G., & Carr, S. A.
- Venue
- Molecular & Cellular Proteomics
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 22
- Issue
- 6
- Pages
- 100563
- ISSN
- 1535-9476
- Cited by
- 54
- References
- 13
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Swiss National Science Foundation (CRSII5_186405)
- National Institutes of Health (P01CA206978)
- National Cancer Institute (U01CA271402, U24CA270823)
- Broad Institute
- Doctor Miriam and Sheldon G Adelson Medical Research Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.